Rating: Cautious Bull | Target Price: $3.00–$5.00 | Current Price: $1.71 (Close 2026-07-13) | Time Horizon: 12–18 Months
So-Young is in the most aggressive transformation experiment among China's light medical aesthetics chain players—shifting entirely from a high-margin online medical aesthetics platform to a self-operated offline clinic chain. At the current price of $1.71, the market cap is only $171 million, while net cash on the books is approximately $112 million (RMB 760 million). Excluding cash, the operating business EV is about $59.3 million, with EV/Sales (TTM) of only 0.26x. Among its 54 self-operated clinics, 41 are profitable at the center level, and revenue growth (Q1 2026 +46%) far exceeds peers. However, the platform business is accelerating its decline (paying institutions -51%), brand reputation is repeatedly damaged (Ma Sichun incident, supplier blacklists), cash flow continues to deteriorate (OCF negative for two consecutive years), and regulatory storms pose material threats. The market is currently pricing the stock near a "zero" pessimistic scenario. If the clinics achieve management's promised single-quarter group-level profitability within 2026, a significant revaluation is likely (fair value baseline $3.00–$5.00). The core tension: can the cash burn rate be covered by revenue growth and profitability improvement before cash runs out?
Key Evidence:
The market's current pricing of the operating business ($59.3 million EV) implies that the clinic business will never achieve large-scale profitability, or the platform business will go to zero. Yet the company generated RMB 1.523 billion in revenue in FY2025, and Q1 2026 revenue grew +46% YoY. This valuation gap is the core starting point of this report.
Important Limitation: Net cash is not entirely freely usable—under the VIE structure, capital outflows require PRC approval (explicitly disclosed in FY2025 20-F risk factors), and cash is being consumed at a rate of approximately RMB 56.5 million per quarter. At this pace, cash will be depleted in about 15–16 quarters. If the core business cannot achieve positive cash flow during this period, the valuation safety cushion will gradually erode.
Key Evidence:
Key Limitation Identified by Red Team: The definition of "center-level profitability" only deducts direct costs such as consumables, personnel, rent, and depreciation. It does not include allocation of group-level selling expenses (RMB 130.8 million in Q1 2026) and administrative expenses (RMB 84.5 million). If headquarters expenses were proportionally allocated, most "profitable" centers might revert to losses—this structural reason explains why "single-store slight profit, group huge loss" has persisted for multiple quarters. Additionally, net additions of core members slowed from 14,500 in Q4 2025 to 11,700 in Q1 2026 (-19% QoQ), suggesting the user base may be approaching a ceiling.
Key Evidence:
So-Young's self-built clinics directly compete with the institutions listed on its platform, causing a large number of B-end clients to withdraw—this is a structural conflict, not a cyclical fluctuation. The remaining 1,858 paid institutions may continue to reduce spending due to competitive pressures. The platform business was once the company's profit center and customer acquisition engine; its collapse not only drags down the profit structure but could also weaken the offline customer acquisition base.
Key Evidence:
For a company transitioning from an online platform to an offline medical chain, trust is the most important intangible asset. So-Young's content review mechanism has never been fundamentally fixed (continuous celebrity lawsuits since 2016), collective upstream supplier boycotts directly threaten the brand promise of "genuine product assurance," and the 14-ministry rectification comes at a time when So-Young's low-price strategy carries the highest risk of compliance violations. These compliance costs are not just compensation and fines but an irreversible erosion of brand trust.
Key Evidence:
Key Constraints Identified by Red Team: ① The mathematical challenge of turning profitable is severe—Q1 2026 net loss of RMB 49.2 million expanded 48.6% YoY (Q1 2025 loss was only RMB 33.1 million), the trend is worsening, not improving; ② SG&A expense ratio is as high as 56% (full year 2025), with selling expenses +34% and administrative expenses +43%, both growing due to store expansion; to achieve breakeven, SG&A must be compressed to below 47% without revenue decline; ③ Gross margin is structurally declining (FY2023 63.7% → Q1 2026 42.0%), and the higher the proportion of low-margin offline business, the lower overall gross margin; ④ Single-quarter profitability does not equal full-year profitability, and the market will not switch from PS to PE valuation based on that.
| Item (RMB million) | FY2023 | FY2024 | FY2025 | Q1 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Revenue | 1,498.0 | 1,466.7 | 1,523.4 | 297.3 | 432.8 |
| Revenue YoY | — | -2.1% | +3.9% | — | +45.6% |
| Net profit attributable to equity holders | 21.3 | -589.5 | -242.3 | -33.1 | -49.2 |
| Non-GAAP net loss | — | -53.2 | — | -31.5 | -46.6 |
| Gross margin | 63.7% | 61.3% | 47.8% | 49.1% | 42.0% |
| Net profit margin attributable to equity holders | 1.4% | -40.2% | -15.9% | -11.1% | -11.4% |
| Operating cash flow (OCF) | 22.5 | -25.6 | -105.4 | — | — |
| Free cash flow (FCF) | -28.7 | -88.1 | -302.0 | — | — |
| Cash & cash equivalents | 1,341.6 | 1,253.1 | 936.4 | — | 879.9 |
| Short-term borrowings | — | — | 39.8 | — | 119.7 |
| Debt-to-asset ratio | 20.3% | 28.4% | 37.0% | — | — |
Reasons for key changes: The sharp decline in gross margin is due to the surge in the low-margin self-operated clinic business share, from 0.9% in FY2023 to 44.3% in FY2025 (over 65% in Q1 2026)—clinic gross margin is ~23–27%, far below the platform's 87%. The large net loss in FY2024 was primarily due to full goodwill impairment of RMB 540 million from the Wuhan Qiji acquisition (FY2025 only recognized a long-term asset impairment of RMB 19.7 million, significantly narrowing the loss). OCF has been net negative for two consecutive years and worsening; management attributes it to working capital occupation from building the clinic network. Short-term borrowings surged from RMB 39.8 million to RMB 119.7 million in Q1 2026, reflecting cash reserve pressure.
So-Young reported Q1 2026 revenue of RMB 432.8 million (+45.6% YoY), slightly above the high end of company guidance. Medical aesthetics treatment services revenue reached RMB 282.4 million (+185.8%), accounting for over 65% of total revenue for the first time; while traditional information and reservation services revenue was only RMB 80.3 million (-34.0%), indicating an accelerating decline of the platform business. Net loss attributable to equity holders was RMB 49.2 million, expanding 48.6% YoY, but significantly narrowing from the RMB 108.8 million loss in Q4 2025 (which included impairment charges).
Management guided Q2 2026 medical aesthetics treatment services revenue of RMB 307–317 million (+112.6%–119.5% YoY) and reiterated the target of achieving single-quarter group-level profitability within 2026 unchanged.
As of Q1 end, So-Young operated 54 clinics (53 self-operated + 1 franchise) across 16 cities; mature clinics (>12 months) generated quarterly revenue of RMB 7.5 million; 41 centers were profitable at the center level (76%), and 48 had positive operating cash flow (89%). Key concerns: ① Net loss expanded YoY instead of narrowing; ② Short-term borrowings tripled to RMB 119.7 million; ③ Cash and equivalents fell to RMB 880 million (quarterly burn of RMB 56.5 million).
Sell-side consensus estimate (FY2026E): Revenue RMB 2.05 billion (+34.4%), EPS -2.36/ADS (still loss-making); median analyst target price $7.31 (2–10 analysts covering, 86% buy consensus)—the huge gap with the current price of $1.71 reflects the market's deep distrust of management's profitability promises.
So-Young started as an online medical aesthetics information platform (like "Dianping for medical aesthetics"). In May 2023, it launched its own light medical aesthetics chain "So-Young Youth Clinics," currently in a mixed transition period of "platform rent collection + self-operated store expansion." Light medical aesthetics (non-surgical: injections + energy-based devices) are characterized by high frequency, standardization, and strong customer stickiness, with the core customer base being office ladies aged 25–35.
The logic behind the transformation: The online platform is squeezed by super traffic portals such as Meituan, Douyin, and Xiaohongshu, leading to rising customer acquisition costs and peak traffic increments → Vertical integration into the midstream of the industry chain, using self-operated clinics to capture the user trust and brand recognition accumulated on the platform → Lower consumable costs through scale procurement, attracting price-sensitive consumers with a "breakthrough the floor" pricing strategy (e.g., Weimei ColPact priced at RMB 1,999/vial, previously similar products > RMB 6,000).
| Item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| OCF/Net profit attributable to equity holders | 0.87 | 0.04 | 0.43 |
| FCF/Net profit attributable to equity holders | -1.11 | 0.15 | 1.22 |
OCF deteriorated from +RMB 22.5 million to -RMB 105.4 million, and FCF (after CapEx) reached -RMB 302.0 million in FY2025. The CapEx/Depreciation ratio surged from 1.11x in FY2023 to 3.44x in FY2025—a typical characteristic of an asset-heavy expansion phase: each year's earnings are far from covering capital expenditures, and each RMB 1 of depreciation corresponds to nearly 3.5x of new investment.
Maintenance CapEx Examination: FY2025 CapEx of RMB 196.6 million (primarily for clinic renovation, equipment procurement, and digital systems), while depreciation and amortization was only RMB 57.2 million. The CapEx/Depreciation ratio of 3.44x is far above the 1.5x warning line, indicating the company is in a capital-intensive expansion stage where profits have not yet converted into cash distributable to shareholders.
FY2025 operating loss was approximately RMB 286 million, invested capital (interest-bearing debt + net equity) was about RMB 2.5 billion, resulting in ROIC of approximately -11%. At this stage, ROIC is not meaningful—the key is the single-store ROIC for mature clinics (>12 months). If a mature store generates annualized revenue of RMB 30 million with a single-store investment of RMB 3–5 million, the clinic-level ROIC could reach 30%+, but at the group level, due to high overhead costs (command center, training center, compliance office, etc.), overall ROIC turning positive will take time.
| Signal | Details |
|---|---|
| OCF negative for two consecutive years and worsening | FY2024 -RMB 26 million → FY2025 -RMB 105 million, accelerating cash burn |
| High-margin platform business shrinking, low-margin clinics expanding | Structurally dragging down overall margin; for every RMB 1 of gross profit lost from platform, clinic needs RMB 4 revenue to compensate |
| Continuous decline in paying institutions and purchasing users | Paying institutions -51%, purchasing users -40%, weakening platform ecosystem |
| Supplier blacklists | Purilayan, Saint Boma, etc., have listed So-Young as a non-official partner institution |
| Supply chain risk | Wuhan Qiji (subsidiary) provides some energy-based devices, but upstream brand manufacturers' collective blockade threatens product supply |
Management has demonstrated execution capability and a prudent style regarding short-term guidance for clinic business expansion. However, the more ambitious promise—"achieving single-quarter group-level profitability within 2026"—remains to be verified. CEO Jin Xing's "thousand-store chain" target (1,000 stores in 8–10 years) is only 5.4% complete; the realization window is too long to serve as an investment decision basis.
Judgment: Pragmatic in the short term, prone to exaggerated expectations in the long term ("thousand-store" narrative).
Judgment: Neutral.
| Segment | FY2025 Revenue Share | FY2025 Gross Margin | FY2025 YoY | Business Logic |
|---|---|---|---|---|
| Medical aesthetics treatment services (self-operated clinics) | 44.3% | 23.1% | +298.7% | Self-built light medical aesthetics chain, non-surgical injection/energy-based procedures, low-margin high-growth expansion phase |
| Information and reservation services (platform) | 32.8% | 87.4% | -32.2% | Medical institution information display + user reservation commission, high margin but accelerating decline |
| Medical product sales and maintenance | 17.6% | 45.1% | -27.2% | Energy-based device and injection product sales through Wuhan Qiji subsidiary |
| Other services | 5.3% | 17.4% | -58.0% | So-Young Prime partnership clinic revenue sharing + insurance brokerage, gradually winding down |
Profit Main Segment: Although information and reservation services only account for 32.8% of revenue, with a gross margin of 87.4%, they contributed approximately 60% of total gross profit (platform gross profit ~RMB 437 million vs clinic gross profit ~RMB 156 million). This means the company's current profit structure remains highly dependent on the old business that is crumbling—for every RMB 1 of revenue lost from information and reservation services, the clinic business needs to grow by about RMB 4 to cover the gross profit gap. Q1 2026 data shows: information revenue decreased by RMB 41.3 million YoY, clinic revenue increased by RMB 183.6 million, yet the overall net loss still expanded by 49%—a direct reflection of the "profit structure imbalance" during the transition.
The gross margin spread is highest (87.4% vs 17.4%) at 70pp, highlighting the fundamental difference between a platform economy (marginal cost approaching zero) and a physical medical chain (asset-heavy consumables + labor + rent).
| Red Flag | Severity | Evidence |
|---|---|---|
| Frequent changes in segment reporting | Medium | Starting FY2024, medical aesthetics treatment services separately disclosed; FY2025 again reclassified—multiple prior-year restatements, making inter-period comparison difficult (FY2025 20-F Item 5) |
| Expanding Non-GAAP metrics | Low | Starting Q4 2024, new exclusions for long-term investment impairment, credit losses, disposal gains/losses—while common adjustments, they increase the gap between Non-GAAP and GAAP |
| Indicator | Pattern | Consistent with Management Explanation? |
|---|---|---|
| OCF vs Net Profit | OCF deteriorated from +22.5 million to -105.4 million, while book losses narrowed | Not specifically explained by the company—none of the three MD&A reports analyzed the reasons for the persistent deterioration in OCF |
| Paying Users | 450,000 → 378,000 → 269,000 (cumulative -40%) | Consistent—each period attributed it to macroeconomic weakness and intensified traffic competition |
| Metric | Value |
|---|---|
| Share Price | $1.71 (close on 2026-07-13) |
| Market Cap | $171.4 million |
| Net Cash | ~$112.1 million (RMB 760 million) |
| EV | ~$59.3 million |
| PS(TTM) | 0.70x |
| EV/Sales(TTM) | 0.26x |
| P/B | 0.61x |
| Avg. Daily Turnover | ~$130,000 (low liquidity) |
The company is not yet profitable, so the PE percentile is not meaningful. The PS percentile is not directly available due to limitations in US stock tools, but compared to peers (Beauty Farm ~2.0x, Lance Medical Beauty ~1.5x), So-Young’s 0.70x is at a deep discount.
Peer Comparison:
| Company | Market Cap (local currency bn) | PE(TTM) | PS(TTM) | Revenue Growth | Gross Margin | ROE |
|---|---|---|---|---|---|---|
| So-Young (SY) | $0.171 bn | Loss | 0.70x | +45.6% (Q1) | 42.0% | Loss |
| Beauty Farm (02373) | ~HKD 4.2 bn | ~19.7x | ~2.0x | +16.7% | 49.1% | 32.3% |
| Lance Co., Ltd. (002612) | ~RMB 9.3 bn | ~29.6x | ~1.5x | +3.3% (Medical Beauty) | 55.8% | 9.7% |
| Ruili Medical Beauty (02135) | ~HKD 0.15 bn | Loss | ~0.5x | -27.3% | Low | -7.5% |
The current price of $1.71 implies the market values the operating business at only ~$59.3 million (EV), corresponding to EV/Sales(TTM) of 0.26x. This level implies the market believes: ① the clinic business will never achieve group-level profitability; ② the platform business will continue to shrink to zero; and ③ cash will keep being consumed until depleted.
In reality: Q1 2026 annualized revenue from the clinic business had already reached RMB 1.13 billion (+186%), 41 out of 54 centers were profitable at the center level, and core member repurchase rate was ~80%. The market’s current pricing essentially refuses to acknowledge these operating results—this is extremely pessimistic pricing.
| Layer | Per-ADS Value | Explanation |
|---|---|---|
| Asset Value (Floor) | ~$2.79 | Net asset per ADS (equity RMB 1.839 bn ÷ FX ÷ ADS count); net cash only included in EPV layer, not double-counted in asset layer |
| EPV Zero Growth | ~$1.95 | Based on normalized EPS of ~$0.10/ADS from current mature clinic annualized profitability, WACC 12%, plus net cash $1.12/ADS |
| Growth Option | Negative | Current price of $1.71 is below EPV of $1.95, implying growth option contributes ~-14%—i.e., the stock trades at a discount to zero-growth value, and the market not only fails to price in growth but discounts existing operating capabilities |
The current price is mostly supported by net cash ($1.12/ADS); the valuation of the operating business is at a deep discount.
| Scenario | Probability | Fair Range | Key Catalyst |
|---|---|---|---|
| Bear | 25% | $0.50–$1.00 | Accelerated platform shrinkage (info revenue -30%+ YoY) + slowed clinic expansion + cash depletion within 12 months forcing dilutive financing |
| Base | 50% | $3.00–$5.00 | Steady clinic expansion to 85–120 units, single-quarter profitability in Q4 2026, breakeven for FY2027; platform stabilizes; EV/Sales returns to 0.5–1.0x |
| Bull | 25% | $7.00–$10.00 | Early turnaround in Q3 2026 + thousand-store model validated + platform traffic recovery + accelerated M&A; EV/Sales converges with Beauty Farm (1.2–1.5x) |
Current price $1.71 sits between the lower half of the bear case and the base case: upside to base case midpoint of $4.00 yields potential return of ~+134%, downside to bear case midpoint of $0.75 yields potential loss of ~-56%. The odds ratio is ~2.4:1, favorable but requires enduring significant volatility.
Valuation Judgement: Undervalued—the current price is below the base-case fair value range ($3.00–$5.00). Target price $3.00–$5.00 (base-case fair value, corresponding to FY2026E PS of 0.5–0.8x, anchored to a ~50–60% PS discount vs Beauty Farm and Lance Medical Beauty, reflecting So-Young’s lack of profitability, negative cash flow, and brand risk). Margin of safety (base-case lower bound $3.00 vs current price) is approximately +75%.
Quality and price separated: This is a company in the midst of a business model transformation, not yet profitable, with damaged brand reputation and deteriorating cash flow (weak quality), but the price is already extremely pessimistic—net cash covers 65% of market cap, the operating business is valued at only $59.3 million, while annualized revenue exceeds RMB 2 billion with a growth rate of 46%.
In 2025, the size of China’s medical aesthetics market is approximately RMB 366.6–370.1 billion (service revenue basis), of which non-surgical (light medical aesthetics) accounts for about RMB 209 billion, or 57%. It is expected that by 2030 the overall market will reach RMB 680.8–700.0 billion, with light medical aesthetics reaching RMB 435.7 billion, accounting for 64%.
China has only 20.8 medical beauty procedures per thousand people, far below South Korea’s 89 and the US’s 59, indicating huge penetration potential. However, the industry is shifting from “scale expansion” to “quality competition”—average spending per customer fell from RMB 6,800 in 2021 to RMB 4,200 in 2023 (a 38.2% decline), with ongoing price wars.
Source: Roland Berger & Meituan Medical Beauty “2025 Medical Beauty White Paper”; Forward Industry Research Institute; Deloitte “China Medical Beauty Industry 2025 Annual Insight Report”.
| Segment | Representative Companies | Gross Margin | Concentration |
|---|---|---|---|
| Upstream (pharmaceuticals/consumables/equipment) | Aimeike, Huaxi Bio, Jinbo Bio, Allergan | 85–95% | High concentration |
| Midstream (medical beauty service providers) | So-Young, Lance, Beauty Farm | 40–60% | Extremely fragmented (CR10 <5%) |
| Downstream (traffic platforms + consumers) | Meituan Medical Beauty, So-Young (online), Douyin, Xiaohongshu | — | Dominated by Meituan/Douyin |
So-Young’s current position: Vertical integration from the downstream (traffic platform) to the midstream (chain clinics). Bargaining power with upstream suppliers is gradually improving as procurement scale expands (direct sourcing from Jinbo Bio, Xihong, Kangzhe, etc.), but remains weaker than large integrated chains. Value in the chain is concentrated in the technologically high-barrier upstream (gross margin 85–95%), while net profit margins in the midstream service segment are generally below 10%.
Demand drivers: Gen Z contributes 62% of consumption share; male share has risen from 14% to 29%; down-market (tier 3 and below) institutions account for 42% of the total. Light medical aesthetics has high repurchase rates; the share of “daily” procedures (hydrafacial/photorejuvenation) has increased from 47.7% to 55.3%.
Supply structure: There are about 19,880 compliant specialized medical beauty institutions (2024H1, excluding public hospitals), dominated by small and medium-sized private players. The industry is extremely fragmented, with CR10 <5%. However, a special rectification campaign in 2024 canceled licenses for over 5,000 non-compliant institutions, accelerating industry consolidation through compliance. 63% of institutions saw revenue decline in 2025H1, and the industry shows a “K-shaped divergence”: high-end anti-aging demand is strong, while the mid-to-low end is mired in price wars.
So-Young’s competitive rank: By number of clinics, So-Young (54) is the largest light medical aesthetics chain in China. Lance operates 43 medical beauty institutions (including general hospitals), and Beauty Farm operates 38 consumer medical institutions plus 552 lifestyle beauty stores.
The light medical aesthetics industry is in a transitional phase from mid-growth to maturity, without typical cyclicality. However, regulatory policies clearly favor compliant leaders:
| Company | Revenue Scale | Revenue Growth | Gross Margin | ROE | Positioning |
|---|---|---|---|---|---|
| So-Young (SY) | RMB 1.523 bn | +3.9% (FY2025) / +46% (Q1 2026) | 42.0% | Loss | Largest light medical aesthetics chain by store count; platform + clinic hybrid |
| Lance Co., Ltd. (002612) | Medical beauty RMB 3.026 bn | +3.3% (Medical Beauty) | 55.8% | 9.7% | Comprehensive medical beauty chain + women’s apparel; 43 institutions |
| Beauty Farm (02373) | RMB 3.0 bn | +16.7% | 49.1% | 32.3% | Largest beauty chain, 552 stores, high-end positioning |
| Meituan Medical Beauty (3690) | Not separately disclosed | ~+4% (Local Commerce) | — | — | Largest medical beauty traffic platform, no self-operated clinics |
| Ruili Medical Beauty (02135) | ~RMB 0.2–0.3 bn | -27.3% | Low | -7.5% | Regional small chain, 4 institutions |
| Aimeike (300896) | ~RMB 2.5 bn | -21.6% | 93.4% | ~15–20% | Upstream injectables leader, not directly comparable |
So-Young is the only listed company in China that has successfully transformed from an internet medical beauty platform into a “platform + offline clinic” hybrid. Sources of moat: ① First-mover scale advantage (54 clinics, the largest light medical aesthetics chain in China); ② Internet DNA (user data and brand awareness accumulated on the platform feed offline customer acquisition); ③ Upstream supply chain partnerships (exclusive cooperation with Jinbo Bio, 20 products under the green-label system); ④ Differentiated positioning—focus on high-frequency, standardized anti-aging procedures for the mass white-collar market, creating a differentiated competitive position versus Beauty Farm (high-end) and Lance (comprehensive).
As a hybrid model transitioning from an internet medical beauty platform to offline chain clinics, the following operational metrics are critical for assessing company quality:
| Metric | FY2023 | FY2024 | FY2025 / Q4 2025 | Q1 2026 |
|---|---|---|---|---|
| Paid Medical Institutions | 3,796 | 2,637 | 1,858 | — |
| Paying Users | 450,100 | 378,400 | 269,500 | — |
| Active Users (12-month) | — | ~52,700 | ~171,000 | ~213,000 |
| Core Members (Level 3+) | — | — | ~51,300 | ~63,000 |
| Number of Clinics | — | — | 49 | 54 |
| Center-Level Profitable Count | — | — | 25/49 (51%) | 41/54 (76%) |
| Verified Treatment Visits (Quarter) | — | ~45,000 | ~125,000 | ~148,000 |
| CAC/Revenue Ratio | — | <10% | <10% | <10% (management estimate) |
| Core Member Repurchase Rate | — | — | >80% | ~80% |
Core contradiction: Active users from offline clinics (213,000) are growing rapidly, but paying users on the online platform (269,500) and paid institutions (1,858) are shrinking at an accelerating pace—the company is completely transitioning from a “light-asset traffic business” to a “heavy-asset chain operation enterprise,” and the synergy between the two businesses (online customer acquisition feeding offline) has not yet been fully proven by data.
Rating: Cautious Bull. The current price of $1.71 corresponds to extremely pessimistic bankruptcy-level pricing (EV only $59.3 million), while the company holds $112.1 million in net cash and an annualized revenue scale exceeding RMB 2 billion. Even considering all negatives—platform collapse, brand crisis, cash flow deterioration—the current price is well below the base-case fair value of $3.00–$5.00.
Catalytic Path: The core observation window is Q2–Q4 2026: ① Can the Q2 earnings report in August confirm the narrowing loss trend? ② Can management deliver on the “single-quarter profitability” promise in Q3/Q4? ③ Outcome of the Ma Sicun lawsuit and brand repair progress. ④ Specific impact of the 14-ministry rectification on So-Young (compliance costs vs. industry consolidation benefits).
Risk Management: Recommend a small position (1–2% of portfolio weight), with a stop-loss at $1.20 (near net cash per ADS—a break below would imply the market begins pricing in unrecoverable cash). Upside target $3.00–$5.00, gradually reducing in 2–3 tranches.
This report is based on public information and internal estimates from Loyan AI and does not constitute investment advice. Data as of 2026-07-14.